870487-48-2

Usage

Uses

Used in Pharmaceutical Industry:
Mes-PEG5-t-butyl ester is used as a solubility enhancer for improving the aqueous solubility of hydrophobic drugs. The hydrophilic PEG linker increases the solubility of these drugs, allowing for better absorption and distribution in the body.
Used in Chemical Synthesis:
Mes-PEG5-t-butyl ester is used as a protecting group in chemical synthesis. The t-butyl group can be selectively removed under acidic conditions, allowing for the controlled release of the desired compound.
Used in Bioconjugation:
Mes-PEG5-t-butyl ester is used as a bioconjugation agent for attaching biologically active molecules to other molecules or surfaces. The mesyl group can participate in substitution reactions, enabling the formation of stable covalent bonds between the PEG linker and the target molecule.
Used in Drug Delivery Systems:
Mes-PEG5-t-butyl ester is used as a component in drug delivery systems, such as nanoparticles or hydrogels, to improve the solubility, stability, and controlled release of therapeutic agents. The PEG linker can also provide stealth properties, reducing the clearance of the drug delivery system by the immune system.

Upstream product

• 124-63-0 methanesulfonyl chloride 
• 518044-32-1 tert-butyl 3-(2-{2-[2-(2-hydroxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)propanoate 
• 1663-39-4 tert-Butyl acrylate 
• 112-60-7 Tetraethylene glycol 

Downstream Products

• 581065-95-4 tert-butyl 3-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]propanoate 
• 663921-15-1 3-[2-(2-{2-[2-(2-aminoethoxy)ethoxy]ethoxy}ethoxy)ethoxy]propanoic acid 

Relevant academic research and scientific papers

DENDRITIC POLYETHYLENE GLYCOL DERIVATIVE, AND PREPARATION METHOD AND APPLICATION THEREOF

The disclosure discloses a dendritic polyethylene glycol derivative and a preparation method and an application thereof. The dendritic polyethylene glycol derivative has a structure of formula (I), has multiple end functional groups, has a stronger water solubility in comparison with linear-chain polyethylene glycol, and can solve a problem of insufficient water solubility due to the increase of load when modifying an insoluble drug by the polyethylene glycol. The preparation method of the dendritic polyethylene glycol derivative provided by the disclosure has mild reaction conditions, is green and environmentally friendly, is low in cost, and is easy to implement industrialization.

STEROIDS AND PROTEIN-CONJUGATES THEREOF

Described herein protein steroid conjugates that are useful, for example, for the target-specific delivery of glucocorticoids (GCs) to cells.

Y-TYPE DISCRETE POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREOF

The present invention discloses a Y-type discrete polyethylene glycol derivative and a preparation method thereof, which has the advantages of determined molecular weights and the number of chain segments, and can avoid the defect of heterogeneity of a PEG derivative, meanwhile the preparation method has simple steps, mild conditions, without need for strictly anhydrous environment or performing protection and deprotection steps. In addition, the Y-type discrete polyethylene glycol derivative of the present invention may increase the water solubility of the discrete polyethylene glycol, and solve the problem of insufficient water solubility of the discrete polyethylene glycol-modified insoluble drug caused by an increase of the loading capacity.

OPTIMIZED TRANSGLUTAMINASE SITE-SPECIFIC ANTIBODY CONJUGATION

Provided herein are methods and compositions for site-specific conjugation of antibodies.

A new route for the synthesis of 1-amino-3,6,9,12-tetraoxapentadecan-15-oic acid

1-Amino-3,6,9,12-tetraoxapentadecan-15-oic acid 8 was synthesised from tetraethylene glycol through a 7 step sequence including esterification, mesylation, azide substitution with subsequent reduction followed by hydrolysis. The structure of product 8 was

Spacer-separated sialyl LewisX cyclopeptide conjugates as potential E-selectin ligands

Completely protected sialyl LewisX azide was synthesized from a neolactosamine azide precursor carrying a 3-O-allyloxycarbonyl group as the temporary protecting group. After its Pd(0)-catalyzed deprotection and stereoselective α-fucosylation, the obtained

CHEMICAL LINKERS AND CONJUGATES THEREOF

The present disclosure provides drug-ligand conjugates that are potent cytotoxins, wherein the drug is linked to the ligand through either a peptidyl, hydrazine, or disulfide linker. The disclosure is also directed to compositions containing the drug-liga